BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 6709108)

  • 1. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
    Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
    [No Abstract]   [Full Text] [Related]  

  • 3. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
    Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
    [No Abstract]   [Full Text] [Related]  

  • 6. [Four cases of therapy-related leukemia in multiple myeloma].
    Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
    Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
    Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma.
    Wilson K; Shelley W; Belch A; Brandes L; Bergsagel D; Klimo P; White D; Willan A
    Cancer Treat Rep; 1987 Oct; 71(10):981-2. PubMed ID: 3652060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy of multiple myeloma].
    Golenkov AK
    Sov Med; 1991; (3):43-6. PubMed ID: 1882290
    [No Abstract]   [Full Text] [Related]  

  • 12. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
    Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
    G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combined treatment, polychemotherapy and amino-hydroxybutylidene-diphosphonate, of a patient with multiple myeloma: remission and long survival].
    Attardo-Parrinello G; Merlini G; Crema F; Fiorentini ML; Mazzone A; Cotti-Piccinelli E
    Medicina (Firenze); 1988; 8(3):318-20. PubMed ID: 3231044
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
    Lila AM; Mazurov VI; Novik AA
    Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578
    [No Abstract]   [Full Text] [Related]  

  • 17. Progress report on vindesine treatment of melphalan-resistant multiple myeloma.
    van Dobbenburgh OA; Houwen B; Halie MR; Marrink J; Ockhuizen T; Nieweg HO
    Eur J Cancer Clin Oncol; 1983 Jun; 19(6):861-2. PubMed ID: 6683653
    [No Abstract]   [Full Text] [Related]  

  • 18. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [VCAP therapy of multiple myeloma].
    Umeda M; Kaneko H; Katoh M; Yamaguchi R; Masaki T; Ishikawa I; Yamauchi M; Kiga Y; Hara A; Nojima Z
    Rinsho Ketsueki; 1987 Jul; 28(7):1147-51. PubMed ID: 3694822
    [No Abstract]   [Full Text] [Related]  

  • 20. [The influence of verapamil on platelet function in patients with multiple myeloma].
    Sokołowska B; Dmoszyńska A; Walter-Croneck A; Wojtaszko M
    Pol Merkur Lekarski; 1997 Feb; 2(8):109-10. PubMed ID: 9538652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.